A randomized clinical trial evaluated the effectiveness and safety of cytisinicline for helping adults quit vaping nicotine. The study involved 160 adults who used nicotine-containing e-cigarettes daily and were not current smokers. Participants were randomly assigned to receive either cytisinicline (3 mg three times daily) or a placebo for 12 weeks, with weekly behavioral support. The primary outcome was continuous e-cigarette abstinence during the last 4 weeks of treatment, confirmed biochemically. Cytisinicline was more effective than placebo, with 31.8% of participants achieving abstinence compared to 15.1% in the placebo group. This effect was also observed during the 4 weeks following treatment. Cytisinicline was well tolerated, with only 3.8% of participants discontinuing the medication due to adverse events. The study found no significant differences in efficacy based on subgroups defined by demographics, vaping patterns, e-cigarette dependence, or smoking history. These results suggest that cytisinicline could be a potential pharmacotherapy for helping adults quit vaping nicotine. However, further research is needed to confirm these findings in a larger trial with longer follow-up. The study highlights the need for effective treatments to help individuals quit vaping, especially given the rising prevalence of e-cigarette use among adults. Cytisinicline, a partial agonist at nicotinic acetylcholine receptors, has shown promise in smoking cessation and may be effective for vaping cessation. The study also notes that e-cigarettes have unique features that distinguish them from combustible cigarettes, requiring tailored approaches for cessation. While the trial provides encouraging results, further research is needed to evaluate the long-term effectiveness and safety of cytisinicline for vaping cessation.A randomized clinical trial evaluated the effectiveness and safety of cytisinicline for helping adults quit vaping nicotine. The study involved 160 adults who used nicotine-containing e-cigarettes daily and were not current smokers. Participants were randomly assigned to receive either cytisinicline (3 mg three times daily) or a placebo for 12 weeks, with weekly behavioral support. The primary outcome was continuous e-cigarette abstinence during the last 4 weeks of treatment, confirmed biochemically. Cytisinicline was more effective than placebo, with 31.8% of participants achieving abstinence compared to 15.1% in the placebo group. This effect was also observed during the 4 weeks following treatment. Cytisinicline was well tolerated, with only 3.8% of participants discontinuing the medication due to adverse events. The study found no significant differences in efficacy based on subgroups defined by demographics, vaping patterns, e-cigarette dependence, or smoking history. These results suggest that cytisinicline could be a potential pharmacotherapy for helping adults quit vaping nicotine. However, further research is needed to confirm these findings in a larger trial with longer follow-up. The study highlights the need for effective treatments to help individuals quit vaping, especially given the rising prevalence of e-cigarette use among adults. Cytisinicline, a partial agonist at nicotinic acetylcholine receptors, has shown promise in smoking cessation and may be effective for vaping cessation. The study also notes that e-cigarettes have unique features that distinguish them from combustible cigarettes, requiring tailored approaches for cessation. While the trial provides encouraging results, further research is needed to evaluate the long-term effectiveness and safety of cytisinicline for vaping cessation.